Printer Friendly

Cowpox with severe generalized eruption, Finland.

Cowpox with a severe, generalized eruption was diagnosed in an atopic 4-year-old girl by electron microscopy, virus isolation, polymerase chain reaction, and immunoglobulin (Ig) M and low-avidity IgG antibodies. The hemagglutinin gene of the isolate clustered with a Russian cowpox virus strain, and more distantly, with other cowpox and vaccinia virus strains. The patient's dog had orthopoxvirus-specific antibodies, indicating a possible transmission route. In Finnish wild rodents, orthopoxvirus seroprevalences were 0%-92%, in humans the semprevalence was 100% in the age group >50, decreasing towards younger age groups.


Cowpox is a zoonotic dermatitis affecting, despite its name, mainly cats and humans. The disease is caused by cowpox virus, a close relative to vaccinia, smallpox (variola), and monkeypox viruses within the Orthopoxvirus genus (1). The relationship between cowpox and vaccinia viruses has been unclear since Edward Jenner used a virus isolate from cows for smallpox vaccination (2,3). Orthopoxviruses, comprising a genus in the family Poxviridae. are large, brick-shaped viruses with a 200-kbp DNA genome, and they replicate in the cytoplasm (4). Because immunity to orthopoxviruses is cross-reactive, smallpox vaccination might have suppressed cowpox virus infections in the human population. Cowpox virus is not highly infective for humans and usually produces a localized lesion mainly on fingers, hands, or face (5). In immunocompromised persons, however, the disease may lead to death (6). The virus infects through skin abrasions, resulting in successive lesions of macular, papular, vesicular, pustular, ulceral, and eschar stages for 2 weeks. Systemic symptoms are also common (5). The reservoir hosts of cowpox are wild rodents (7); wild rodents may transmit the virus to humans through cats (5) or other pets that roam outside. Direct transmission from a rodent to a girl has been recently described (8). Both cowpox and monkeypox, which was recently transmitted to the United States by transport of animals indigenous to Africa (9), are actually orthopoxviruses of their reservoir rodents and are not well adapted to interhuman spread (1). The misleading nomenclature is based on the hosts from which they were first identified (l). Cowpox virus infections have been detected in Europe and central and northern Asia (1). Nongeneralized infections in children have been previously characterized and diagnosed by electron microscopy (10), virus isolation, polymerase chain reaction (PCR), and restriction enzyme analysis (10,11).

The Study

A 4-year-old girl from a small farm in eastern Finland was hospitalized in September 2000 because of umbilicated vesicopapules, which developed over the previous 5 days (Figure 1), and unresponsiveness to cephalexin. She had a past history of moderate atopic dermatitis. Animals at her home farm included a horse, three dogs, and a rabbit, but she had no contact with cats because of allergy. On examination, most lesions were located on her swollen red extremities, a few were found on the side of her body, and 3-mm lesions were found on the face and vulva. All lesions were at the same stage of development. She was febrile with 38 [degrees] C temperature and feeling unwell. A biopsy sample from a papule was sent to a virology laboratory, where orthopoxvirus particles 230 x 300 nm in size were demonstrated by electron microscopy with negative staining.


The girl was treated in isolation at the hospital with chlorhexidine washings and wound dressings with fusidic acid. Intravenous dicloxacillin was administered to prevent secondary bacterial infections. On day 12, skin lesions progressed to deep-seated, hard, black eschars. At the same time the patient's general condition improved. Two months later, all lesions were healed with scars. A homogenized biopsy sample was used to infect Veto cells, where a cytopathic effect typical of orthopoxviruses was seen after 2 days. The isolate, designated CPXV/FIN/T2000, was shown to contain orthopoxvirus by electron microscopy, and DNA samples from both the infected cells and the original biopsy specimen were PCR-positive for orthopoxvirus thymidine kinase gene (12). The hemagglutinin (HA) gene of the isolate was amplified (13), sequenced (948 nucleotides; accession no. AY366477), and compared to other orthopoxviruses. The CPXV/FIN/T2000 strain differed 3% to 4% at the nucleotide level from cowpox virus strains available in GenBank. The sequences were further subjected to phylogenetic analysis: they were aligned by using Clustal X with Gonnet protein matrix and analyzed by using the maximum likelihood phylogcnetic software TREE-PUZZLE 5.0, applying the Hasegawa model of substitution and per forming 25,000 steps. The HA sequence of CPXV/FIN/T2000 formed a separate clade with cowpox virus strain GRI-90 (Figure 2), isolated originally from another 4-year-old girl, who contracted cowpox after playing with a mole near Moscow (14). The reference cowpox virus strain Brighton grouped with camelpox and variola viruses instead of other cowpox or vaccinia viruses. However, because of the high homology of HA genes, this finding should be interpreted with caution. The remaining cowpox virus strains clustered together with vaccinia viruses; this clustering may, in some cases, be explained by origin from vaccinia virus strains that had escaped to nature (13). This finding seems not to be the case in Finland, since the HA nucleotide sequence of vaccinia virus used in Finland differed 4% both from the strain CPXV/FIN/T2000 and another Finnish cowpox virus isolate from 1989 with an identical HA sequence (data not shown). Different alignment parameters and the neighbor-joining method produced the same results with high support values. Scattered phylogenetic distribution of cowpox virus strains is supported by data presented by other researchers and may reflect an ancestral role of cowpox viruses within the Orthopoxvirus genus; some strains cluster with vaccinia viruses and others (including the reference Brighton strain) with variola virus (1).


An immunofluorescence assay (IFA) to measure specific immunoglobulin (Ig) G, IgM, and avidity of IgG antibodies (15) was established on acetone-fixed, CPXV/FIN/T2000-strain-infected Vero cells. The patient's serum had a high IgM-antibody titer at admission and low avidity of specific IgG; after 60 days, the IgM level was low and the IgG avidity high (Table 1).

The serum samples from the patient's pets were collected later and tested with IFA. A hunting dog had antibodies with a titer of 320; another dog had a titer of 20. Thus, a dog might have transmitted the infection from a wild rodent to the patient, although cats are thought to be the main source of human infection (5).

We further studied orthopoxvirus antibodies by IFA in Finnish fauna and humans. The seroprevalence rates for cats and horses were 3.9% and 1.6%, respectively; the rates for wild rodents (when either serum or lung or heart extracts was used) were 0%0 to 92%, depending on the trapping time and the location (Table 2). In Vartsila, a rural district in eastern Finland near where the patient lives, anti-bodies were found in 1 (2.8%) of 36 rodents. However, variation of seroprevalence rates in rodents is also influenced by population dynamics: low prevalences are often found in the increase phase and high prevalences in the peak phase of rodent population fluctuations. The positive rodents were mainly bank voles (Clethrionomys glareolus). The two seropositive horses were from a region near where the patient lives in eastern Finland, and the three seropositive cats were free-roaming and found in southern Finland.

In addition, seroprevalence rates of 50% (7/14) mad 1.4% (1/73) have been found in foxes and lynxes, respectively, from a limited geographic area in Finland (16). Sera collected at a Finnish Veterinary meeting in 2001 showed that every person >50 years had orthopoxvirus antibodies, as measured by IFA. The seroprevalenee decreased gradually for younger age groups (Table 3), reflecting the gradual cessation of smallpox vaccination (the last vaccinations in Finland occurred in 1977). The average population might have lower seroprevalence rates than veterinarians because of veterinarians' frequent contact with animals that may harbor orthopoxvirus. Consequently, younger age groups are more susceptible to smallpox and cowpox virus infections.

Although cowpox virus infection usually causes a single, painful, ulcerated vesicopustule and local lymphadenopathy, immunocompromised patients and children, especially those with atopic eczema, are susceptible to a generalized, even lethal, smallpoxlike infection (5,6). An early diagnosis and prompt recognition of the virus are essential for treating and differentiating cowpox, from other orthopoxvirus and herpesvirus infections, especially in severe cases.


Cowpox virus (orthopoxvirus) infection was diagnosed by electron microscopy, PCR, virus isolation, and serologic testing (positive IgM or low avidity of IgG antibodies). Cowpox virus strains show considerable genetic variations with different positioning in the orthopoxvirus phylogenetic tree. Circulation of cowpox virus in wild and domestic animals, together with decreased immunity in humans, may lead to increased occurrence of human cowpox, especially in atopic and immunocompromised persons who are at risk for generalized infection. The described case further suggests atopy to be a contraindication to smallpox vaccination.

Table 1. Orthopoxvirus antibodies in sera of the patient
and her pets (a)


Characteristic IgM IgG IgG avidity (%)

Patient day 7 1280 2560 1.5
Patient day 14 640 2560 3.1
Patient day 60 10 640 25
Old-immunity controls (>50 y) <10 80-640 50-100
Negative controls <10 <10 --
Dog A -- <20 --
Dog B -- 320 50
Dog C -- 20 50
Horse -- <20 --
Rabbit -- <20 --

(a) Ig, immunoglobulin.

Table 2. Orthopoxvirus antibodies in cat, horse, and wild rodent
panels, Finland

Panel n Positive Prevalence (%)

Cats 77 3 3.9
Horses 127 2 1.6
Wild rodents
 Southern Finland: Evo 36 33 91.7
 Eastern Finland: Vartsila 36 1 2.8
 Western and central Finland:
 Several localities 436 0 0
 Lapland: several localities 394 7 1.8 (0.4-15.2)
Wild rodents altogether 902 41 4.5

Table 3. Orthopoxvirus antibodies in humans (veterinarians),

Humans (y) n Positive Prevalence (%)

[less than or equal to] 25 19 2 10.5
26-30 23 4 17.4
31-50 78 46 59.0
[greater than or equal to] 51 18 18 100.0


We thank the personnel of North Karelia Central Hospital and the patient's family for their efforts and cooperation; veterinarians from Tornio and Joensuu, the Central Laboratory of the Veterinary Teaching Hospital, and the Helsinki and Porvoo Animal Protection Societies for animal serum samples; and Tytti Manni for excellent laboratory assistance.

This work was funded by the University of Helsinki and supported by the EU grant QLR2-CT-2002-01358, the Farmos Foundation for Research and Science, and the Foundation for Support of Veterinary Research.

Dr. Pelkonen is a doctor of veterinary medicine and a researcher at the University of Helsinki, both in the Department of Virology, Faculty of Medicine, and the Division of Microbiology and Epidemiology, Faculty of Veterinary Medicine. She is a doctoral student in virology and is developing diagnostic methods and studying molecular epidemiology, disease associations, and reservoirs of orthopox and Borna disease viruses.


(1.) Esposito JJ, Fenner F. Poxviruses. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2885-921.

(2.) Jenner E. An inquiry into the causes and effects of the variola vaccine, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cowpox. London: Sampson Low; 1798.

(3.) Baxby D. Edward Jenner's inquiry; a bicentenary analysis. Vaccine 1999;17:301-7.

(4.) Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2849-83.

(5.) Baxby D, Bennett M. Getty B. Human cowpox 1969-93: a review based on 54 cases. Br J Dermatol 1994;131:598-607.

(6.) Czerny CP, Eis-Hubinger AM, Mayr A, Schneweis KE, Pteiff B. Animal poxviruses transmitted from cat to man: current event with lethal end. J Vet Med 1991;B38:421-31.

(7.) Chantrey J, Meyer H. Baxby D, Begon M, Bown KJ, Hazel SM, et al. Cowpox: reservoir hosts and geographic range. Epidemiol Infect 1999: 122:455-60.

(8.) Wolfs TFW, Wagenaar JA, Niesters HGM. Osterhaus ADME. Rat-to-human transmission of cowpox infection. Emerg Infect Dis 2002;8:1495-6.

(9.) Larkin M. Monkeypox spreads as US public-health system plays catch-up. Lancet Infect Dis 2003;3:461.

(10). Wicnecke R. Wolff H, Schaller M, Meyer H, Plewig G. Cowpox virus infection in an 11-year-old girl. J Am Acad Dermatol 2000:42:892-4.

(11). Schupp P, Pfeffer M, Meyer 11, Burck G. Kolmel K, Neumann C. Cowpox virus in a 12-year-old boy: rapid identification by an orthopoxvirus-specific polymerase chain reaction. Br J Dermatol 2001;145:146-50.

(12) Sandvik T, Tryland M. Hansen H, Mehl R. Moens U, Olsvik O, et al. Naturally occurring orthopoxviruses: potential for recombination with vaccine vectors. J Clin Microbiol 1998;36:2542-7.

(13.) Damaso CRA, Esposito JJ, Condit RC, Moussatche N. An emergent poxvirus from humans and cattle in Rio dc Janeiro state: Catagalo virus may derive from Brazilian smallpox vaccine. Virology 2000;277:439-49.

(14.) Marennikova SS, Gashnikov PV, Zhukova OA, Ryabchikova El. Streltsov VV. Ryazankina OI. el al. Biotype and genetic characterization of isolate of cowpox virus having caused infection in a child. Zh Mikrobiol Epidemiol Immunobiol. 1996;4:6-10.

(15.) Hedman K, Vaheri A, Brummer-Korvenkontio M. Rapid diagnosis of hantavirus disease with an IgG avidity assay. Lancet 1991;338:1353-6.

(16.) Tryland M, Sandvik T, Arnemo JM, Stuve G, Olsvik [empty set], Traavik T. Antibodies against orthopoxviruses in wild carnivores from Fennoscandia. J Wildl Dis 1998;34:443-50.

Address for correspondence to: Paula Pelkonen, Department of Virology. Haartman Institute. P.O.B. 21, FIN-00014 University of Helsinki. Helsinki, Finland: fax: +358 9 191 26491: email:

* Faculty of Veterinary Medicine, Helsinki, Finland; Haartman Institute, Helsinki, Finland; [double dagger] Central Hospital of North Karelia, Joensuu, Finland;

Paula M. Pelkonen, * [dagger] Kyllikki Tarvainen, [double dagger] Arja Hynninen [double dagger] Eva R.K. Kallio, [section] Heikki Henttonen, [section] Airi Palva, * Antti Vaheri, [dagger] [paragraph] and Olli Vapalahti * [dagger] [paragraph]

* Faculty of Veterinary Medicine, Helsinki, Finland; [dagger] Haartman Institute, Helsinki, Finland; [double dagger] Central Hospital of North Karelia, Joensuu, Finland; [section] Finish Forest Research Institute, Vantaa, Finland; and [paragraph] HUCH Laboratory Diagnostics, Helsinki, Finland
COPYRIGHT 2003 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Dispatches
Author:Vapalahti, Olli
Publication:Emerging Infectious Diseases
Geographic Code:4EUFI
Date:Nov 1, 2003
Previous Article:Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in Salmonella enterica Typhimurium isolates in humans.
Next Article:Pulmonary tuberculosis due to Mycobacterium bovis subsp. caprae in captive Siberian tiger.

Related Articles
To kill a killer?
Japanese color woodcut print advertising the effectiveness of cowpox vaccine.
[Translation of front cover text] Use of Vaccine Has Spread from Osaka to Edo (Tokyo) for the Benefit of Mankind.
Brave new drug: compound stops cowpox and smallpox viruses.
Rat-to-human transmission of Cowpox infection. (Dispatches).
Carrell, Jennifer Lee. The speckled monster; a historical tale of battling smallpox.
Cooney, Caroline B. Code orange.
Cowpox virus transmission from rats to monkeys, the Netherlands.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters